Influence of glutamine and glycyl-glutamine on in vitro lymphocyte proliferation in children with solid tumors.

Abstract

It is reported that the proliferative response of lymphocytes is lowered in patients with solid tumors. Glutamine is a major nutrient for rapidly proliferating cells. Unlike glutamine itself, the dipeptide glycyl-glutamine as a source for glutamine is stable in aqueous solutions ex vivo. In order to evaluate the possible therapeutic role of glutamine in lymphocyte proliferation, we investigated its influence on lymphocytes of children with solid tumors before and after chemotherapy. Lymphocytes were collected from 21 children and adolescents suffering from solid tumors (before and after chemotherapy) and from healthy controls. Glutamine and glycyl-glutamine, respectively, were added to cell cultures at concentrations between zero and 1.0 mmol/l. ConA or SAC served as T- or B-cell mitogens, respectively. The lymphocyte proliferation in the healthy control group was similar in degree to lymphocyte proliferation seen in the patients with solid tumors, regardless of the mitogen used. No difference in the degree of lymphocyte proliferation before or after chemotherapy was seen with either source of glutamine. Specific subgroups of malignancies showed trends that differed from the overall findings, but these differences were not found to be statistically significant. Routine supplementation with glutamine in children with solid tumors to enhance lymphocyte function is not supported by the data gained from in vitro proliferation tests.